Description: Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Home Page: www.staybletherapeutics.se
Arvid Hedvalls Backe 4
Gothenburg,
411 33
Sweden
Phone:
46 7 30 80 83 97
Officers
| Name | Title |
|---|---|
| Mr. Andreas Gerward M.Sc. | Co-Founder & CEO |
| Mr. Mattias Munnich M.Sc. | Co-Founder & Chief Operating Officer |
| Mr. Thomas Palsson M.Sc. | Chief Financial Officer |
| Mr. Anders Lehmann Ph.D. | Chief Scientific Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8474 |
| Price-to-Sales TTM: | 213.8116 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |